Please wait a minute...
文章检索
预防医学  2023, Vol. 35 Issue (2): 126-129,133    DOI: 10.19485/j.cnki.issn2096-5087.2023.02.008
  综述 本期目录 | 过刊浏览 | 高级检索 |
骨科术后患者排便障碍的影响因素及干预研究进展
倪晶1, 马超猛1, 项思成1, 贾翁萍1, 张燕1 综述, 徐利2 审校
1.浙江中医药大学第一临床医学院,浙江 杭州 310053;
2.浙江中医药大学附属第一医院,浙江 杭州 310006
Influencing factors and interventions of defecation disorders after orthopedic surgery: a review
NI Jing1, MA Chaomeng1, XIANG Sicheng1, JIA Wengping1, ZHANG Yan1, XU Li2
1. The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China;
2. The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, China
全文: PDF(893 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 排便障碍是骨科术后最常见的并发症之一,可严重影响患者生活质量。本文通过查阅近年来关于术后排便障碍影响因素及干预的国内外文献,分析骨科手术相关因素与术后排便障碍的关系,并从药物治疗、物理治疗及日常生活管理等方面总结术后排便障碍的常用干预方法,为骨科术后患者排便障碍的预防及干预提供参考。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
倪晶
马超猛
项思成
贾翁萍
张燕
徐利
关键词 骨科手术排便障碍影响因素阿片类药物干预    
Abstract:Defecation disorder is one of the most common complications after orthopedic surgery, which seriously affects patients' quality of life. Based on review of national and international publications pertaining to influencing factors and interventions of postoperative defecation disorders, this review analyzes the associations of orthopedic surgery-related factors with postoperative defecation disorders, and summarizes the common interventions for postoperative defecation disorders, including medication, physical therapy and daily life management, so as to provide insights into prevention and treatment of defecation disorders after orthopedic surgery.
Key wordsorthopedic surgery    defecation disorder    influencing factor    opioids    intervention
收稿日期: 2022-09-26      修回日期: 2022-12-02      出版日期: 2023-02-10
中图分类号:  R816.8  
基金资助:国家自然科学基金(81704082); 浙江省医药卫生科技项目(2020384124)
作者简介: 倪晶,硕士研究生在读
通信作者: 徐利,E-mail:20053012@zcmu.edu.cn   
引用本文:   
倪晶, 马超猛, 项思成, 贾翁萍, 张燕, 徐利. 骨科术后患者排便障碍的影响因素及干预研究进展[J]. 预防医学, 2023, 35(2): 126-129,133.
NI Jing, MA Chaomeng, XIANG Sicheng, JIA Wengping, ZHANG Yan, XU Li. Influencing factors and interventions of defecation disorders after orthopedic surgery: a review. Preventive Medicine, 2023, 35(2): 126-129,133.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2023.02.008      或      https://www.zjyfyxzz.com/CN/Y2023/V35/I2/126
[1] ROSS-ADJIE G M,MONTEROSSO L,BULSARA M.Bowel management post major joint arthroplasty:results from a randomised controlled trial[J].Int J Orthop Trauma Nurs,2015,19(2):92-101.
[2] 颜廷法,李倩倩,孙飞,等.关节置换患者术后便秘的相关因素分析[J].泰山医学院学报,2019,40(7):505-508.
[3] 陈巧林. 关节置换患者术后便秘的相关因素与护理对策[J].中国社区医师,2017,33(21):145-146.
[4] PODZEMNY V,PESCATORI L C,PESCATORI M.Management of obstructed defecation[J].World J Gastroenterol,2015,21(4):1053-1060.
[5] HOLTE K,KEHLET H.Postoperative ileus:a preventable event[J].Br J Surg,2000,87(11):1480-1493.
[6] MCCORMICK D.Managing costs and care for chronic idiopathic constipation[J].Am J Manag Care,2019,25(Suppl.4):S63-S69.
[7] ARTINYAN A,NUNOO-MENSAH J W,BALASUBRAMANIAM S,et al.Prolonged postoperative ileus-definition,risk factors,and predictors after surgery[J].World J Surg,2008,32(7):1495-1500.
[8] 刘菊新. 骨科长期卧床病人便秘原因的分析与对策[J].长治医学院学报,2004(1):64-65.
[9] FARMER A D,HOLT C B,DOWNES T J,et al.Pathophysiology,diagnosis,and management of opioid-induced constipation[J].Lancet Gastroenterol Hepatol,2018,3(3):203-212.
[10] 刘立波,陈朝军,凌洁.骨科卧床病人便秘原因分析及护理对策[J].湖南师范大学学报(医学版),2010,7(3):72-74.
[11] KIELY P D,MOUNT L E,DU J Y,et al.The incidence and risk factors for post-operative ileus after spinal fusion surgery:a multivariate analysis[J].Int Orthop,2016,40(6):1067-1074.
[12] AL MAAIEH M A,DU J Y,AICHMAIR A,et al.Multivariate analysis on risk factors for postoperative ileus after lateral lumbar interbody fusion[J].Spine,2014,39(8):688-694.
[13] 唐雨亭,方立俭.骶神经刺激疗法治疗便秘的现状及机制探讨[J].吉林医学,2018,39(4):745-748.
[14] HOLZER P.Opioid receptors in the gastrointestinal tract[J].Regul Pept,2009,155(1/2/3):11-17.
[15] CHEN C,ZHANG L,ALMANSA C,et al.Evaluation of the pharmacokinetics of felcisetrag(TAK-954),a 5-HT4 receptor agonist,in the presence and absence of itraconazole,a potent CYP3A4 inhibitor[J].Clin Pharmacol Drug Dev,2022,11(2):142-149.
[16] BENYAMIN R,TRESCOT A,DATTA S,et al.Opioid complications and side effects[J].Pain Physician,2008,11:S105-S120.
[17] COLVIN L A,BULL F,HALES T G.Perioperative opioid analgesia-when is enough too much?A review of opioid-induced tolerance and hyperalgesia[J].Lancet,2019,393(10180):1558-1568.
[18] SINGLA N K,SKOBIERANDA F,SOERGEL D G,et al.APOLLO-2:a Randomized,Placebo and Active-Controlled Phase Ⅲ study investigating oliceridine(TRV130),a G protein-biased ligand at the μ-opioid receptor,for management of moderate to severe acute pain following abdominoplasty[J].Pain Practice,2019,19(7):715-731.
[19] LEPPERT W,ZAJACZKOWSKA R,WORDLICZEK J.The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation[J].Expert Opin Pharmacother,2019,20(5):511-522.
[20] YUAN C S,FOSS J F.Methylnaltrexone:investigation of clinical applications[J].Drug Dev Res,2000,50(2):133-141.
[21] FLOETTMANN E,BUI K,SOSTEK M,et al.Pharmacologic profile of naloxegol,a peripherally acting µ-opioid receptor antagonist,for the treatment of opioid-induced constipation[J].J Pharmacol Exp Ther,2017,361(2):280-291.
[22] 韦良臣,谭振,周报春,等.莫沙必利联合地塞米松对全膝关节置换术术后早期康复的影响[J].中华实用诊断与治疗杂志,2021,35(12):1285-1289.
[23] SWARM R A,PAICE J A,ANGHELESCU D L,et al.Adult cancer pain,version 3.2019,NCCN clinical practice guidelines in oncology[J/OL].J Natl Compr Canc Netw,2019,17(8)[2022-12-17].https://doi.org/10.6004/jnccn.2019.0038.
[24] LACY B E,LEVY L C.Lubiprostone:a novel treatment for chronic constipation[J].Clin Interv Aging,2008,3(2):357-364.
[25] LEMBO A J,JOHANSON J F,PARKMAN H P,et al.Long-term safety and effectiveness of lubiprostone,a chloride channel(ClC-2)activator,in patients with chronic idiopathic constipation[J].Dig Dis Sci,2011,56(9):2639-2645.
[26] SHAH E D,KIM H M,SCHOENFELD P.Efficacy and tolerability of guanylate cyclase-c agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation:a systematic review and meta-analysis[J].Am J Gastroenterol,2018,113(3):329-338.
[27] NAKAJIMA A,TANIGUCHI S,KUROSU S,et al.Efficacy,long-term safety,and impact on quality of life of elobixibat in more severe constipation:post hoc analyses of two phase 3 trials in Japan[J/OL].Neurogastroenterol Motil,2019,31(5)[2022-12-02].https://doi.org/10.1111/nmo.13571.
[28] HUSSAIN Z H,WHITEHEAD D A,LACY B E.Fecal Impaction[J/OL].Curr Gastroenterol Rep,2014,16(9)[2022-12-02].https://doi.org/10.1007/s11894-014-0404-2.
[29] MORI H,TACK J,SUZUKI H.Magnesium oxide in constipation[J/OL].Nutrients,2021,13(2)[2022-12-02].https://doi.org/10.3390/nu13020421.
[30] RAO S S.Biofeedback therapy for constipation in adults[J].Best Pract Res Clin Gastroenterol,2011,25(1):159-166.
[31] ZHOU S L,ZHANG X L,WANG J H.Comparison of electroacupuncture and medical treatment for functional constipation:a systematic review and meta-analysis[J].Acupunct Med,2017,35(5):324-331.
[32] 于凌. 针灸治疗胸腰椎骨折术后腹胀便秘的临床疗效[J].中外女性健康研究,2018(12):28-29.
[33] BAE S H.Diets for constipation[J].Pediatric Gastroenterol Hepatol Nutr,2014,17(4):203-208.
[34] ROSENBAUM D P,YAN A,JACOBS J W.Pharmacodynamics,safety,and tolerability of the NHE3 inhibitor tenapanor:two trials in healthy volunteers[J].Clin Drug Investig,2018,38(4):341-351.
[35] CAMILLERI M,FORD A C,MAWE G M,et al.Chronic constipation[J/OL].Nat Rev Dis Primers,2017,3(1)[2022-12-02].https://doi.org/10.1038/nrdp.2017.95.
[1] 吴成慧, 彭艳红, 张可, 朱维晔, 邓亮, 谭玲玲, 瞿丹丹, 米秋香. 中青年2型糖尿病患者益处发现的影响因素分析[J]. 预防医学, 2026, 38(1): 31-35.
[2] 徐光明, 张震, 叶小红. 2015—2024年临海市新报告HIV/AIDS病例晚发现及影响因素分析[J]. 预防医学, 2026, 38(1): 71-74.
[3] 夏子淇, 陈晴晴, 高四海, 吴矛矛. 温州市中小学生营养健康知识调查[J]. 预防医学, 2026, 38(1): 98-101,106.
[4] 陈慧, 苗姗姗, 刘宪峰, 张慧. 新疆生产建设兵团中小学生龋齿现况调查[J]. 预防医学, 2026, 38(1): 102-106.
[5] 吕婧, 徐欣颖, 乔颖异, 石兴龙, 岳芳, 刘营, 程传龙, 张宇琦, 孙继民, 李秀君. 浙江省发热伴血小板减少综合征流行特征及影响因素分析[J]. 预防医学, 2026, 38(1): 10-14.
[6] 陶桃, 张海芳, 凡鹏飞, 李秋华, 陈晓蕾. 丽水市老年肺结核患者治疗转归的影响因素分析[J]. 预防医学, 2025, 37(9): 892-896,902.
[7] 徐艳平, 闫晓彤, 姚丁铭, 徐越, 张雪海, 孙洁, 徐锦杭. 浙江省中老年人肺炎疫苗接种意愿的影响因素研究[J]. 预防医学, 2025, 37(9): 881-885.
[8] 姜艳, 李锦成, 许纯, 杨科佼, 杨文彬, 徐胜. 扬州市MSM人群艾滋病非职业暴露后预防知晓率调查[J]. 预防医学, 2025, 37(9): 903-906,912.
[9] 宋臻, 张嘉怡, 吴大东, 综述;龚霓, 审校. 围产期抑郁数字健康干预平台的研究进展[J]. 预防医学, 2025, 37(9): 907-912.
[10] 翟羽佳, 章涛, 古雪, 徐乐, 吴梦娜, 林君芬, 吴晨. 社区老年人认知衰弱现况调查[J]. 预防医学, 2025, 37(8): 762-766,772.
[11] 苏德华, 陈向阳, 李君, 赵丽娜, 张鹤美, 朱婷婷, 胡文雪, 赖江宜. 温州市新报告HIV/AIDS病例抗病毒治疗及时性分析[J]. 预防医学, 2025, 37(8): 804-808.
[12] 严青秀, 王炜, 郝晓刚, 高宇, 方春福, 张幸, 刘文峰. 2017—2023年衢州市肺结核患者未收治情况分析[J]. 预防医学, 2025, 37(8): 799-803.
[13] 王晓宇, 张志平, 董玉颖, 梁杰, 陈强. 老年人带状疱疹疫苗接种意愿的影响因素分析[J]. 预防医学, 2025, 37(8): 809-813.
[14] 王海琪, 张涵潇, 杨凤云, 国献丽, 范生荣, 张丽锋, 蒋泓. 嘉定区中学生抑郁情绪调查[J]. 预防医学, 2025, 37(8): 832-836.
[15] 成灵灵, 阎亚琼, 白增华, 张晓刚, 郝丽婷, 杨慧莹. 先天性甲状腺功能减退症患儿年龄别体质指数Z评分变化轨迹及影响因素[J]. 预防医学, 2025, 37(8): 858-863.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed